Off-label Prescribing Among Office-Based Physicians

Cited by (710)

Items 701–710 of 710

1. When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities
   Joshua Mitchell, Benjamin Bregman, Renuka Surujnarain, Dominic A. Sisti, Amy L. McGuire · 2026 · Psychiatric Services
2. Genetically supported drug target prioritization for rare diseases
   Robert E. Chen, Áine Duffy, Matthew E. Mort, D.N. Cooper, Ghislain Rocheleau, Daniel M. Jordan, Ron Do · 2026 · Genome Medicine
3. Strategic Submissions: An Analysis of Supplemental Drug Approvals
   Pierre Dubois, Elissa Philip Gentry, Tuba Tunçel · 2026 · Journal of Economics & Management Strategy
4. The long shadow of typhoons: Prenatal exposure and adult mental health
   Yu-Ting Huang, Elaine M. Liu, Jin‐Tan Liu, Tzu-Yin Hazel Tseng · 2026 · Journal of Development Economics
5. Off‐Label Prescribing as Therapeutic Governance: Regulation and Inequality in Contemporary Medicine
   Enrique Fernández Vilas, Raquel Coca-Asensio, David Casado Neira, Manuel Torres‐Cubeiro, Marcos Iglesias Carrera, Juan R. Coca · 2026 · Sociology Lens
6. Physicians’ Judgments About Off-Label Medical Narcotic Use and Dose Reduction Responses: A South Korean Cross-Sectional Survey
   Yongsoo Lee, Yang‐Ki Minn, Jung Eun Kim · 2026 · Medicina
7. Gabapentin Use in Medicaid After Descheduling
   Katherine Gora Combs, Wei‐Hsuan Lo‐Ciganic, Jingye Yang, Juan M. Hincapie‐Castillo · 2026 · JAMA Network Open
8. Off-label drug use in children: prevalence, risks, and regulation
   Antje C. Neubert, Sonja Eberl · 2026 · Expert Review of Clinical Pharmacology
9. Personal Health Data for Sale: Lessons from the European Union to Strengthen Canadian Privacy
   Madeline Y. Lownie, Marc‐André Gagnon · 2026 · International Journal of Social Determinants of Health and Health Services
10. Conclusion
    Jules J. Berman · 2014 · Elsevier eBooks